Published in Ann Neurol on December 01, 1989
Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet (2003) 3.39
Mitochondrial DNA sequence variation in human evolution and disease. Proc Natl Acad Sci U S A (1994) 2.96
Glutathione dysregulation and the etiology and progression of human diseases. Biol Chem (2009) 2.70
alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol (2000) 2.36
D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. J Clin Invest (2003) 2.25
Lewy bodies. Proc Natl Acad Sci U S A (2006) 2.15
Anemia or low hemoglobin levels preceding Parkinson disease: a case-control study. Neurology (2009) 2.09
Somatic mitochondrial DNA mutations in early Parkinson and incidental Lewy body disease. Ann Neurol (2012) 2.08
PINK1- and Parkin-mediated mitophagy at a glance. J Cell Sci (2012) 1.89
The role of oxidative stress in Parkinson's disease. J Parkinsons Dis (2013) 1.86
Use of transmitochondrial cybrids to assign a complex I defect to the mitochondrial DNA-encoded NADH dehydrogenase subunit 6 gene mutation at nucleotide pair 14459 that causes Leber hereditary optic neuropathy and dystonia. Mol Cell Biol (1996) 1.76
The development of mitochondrial medicine. Proc Natl Acad Sci U S A (1994) 1.68
Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. Proc Natl Acad Sci U S A (2005) 1.68
Mitochondrial complex I inhibition is not required for dopaminergic neuron death induced by rotenone, MPP+, or paraquat. Proc Natl Acad Sci U S A (2008) 1.61
Complex I deficiency in Parkinson's disease frontal cortex. Brain Res (2007) 1.61
Alpha-ketoglutarate dehydrogenase: a target and generator of oxidative stress. Philos Trans R Soc Lond B Biol Sci (2005) 1.55
Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's disease. Proc Natl Acad Sci U S A (2007) 1.41
Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A (2003) 1.40
Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism. Neurobiol Dis (2012) 1.39
Redox imbalance in Parkinson's disease. Biochim Biophys Acta (2008) 1.39
Role of reactive oxygen species in the neurotoxicity of environmental agents implicated in Parkinson's disease. Free Radic Biol Med (2008) 1.38
Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA (2015) 1.37
A guide to neurotoxic animal models of Parkinson's disease. Cold Spring Harb Perspect Med (2011) 1.36
Near-infrared light via light-emitting diode treatment is therapeutic against rotenone- and 1-methyl-4-phenylpyridinium ion-induced neurotoxicity. Neuroscience (2008) 1.35
Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. Biochim Biophys Acta (2008) 1.35
Differential cytotoxicity of Mn(II) and Mn(III): special reference to mitochondrial [Fe-S] containing enzymes. Toxicol Appl Pharmacol (2001) 1.35
Integrating pathways of Parkinson's disease in a molecular interaction map. Mol Neurobiol (2013) 1.34
The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives. Biochim Biophys Acta (2013) 1.34
6-Hydroxydopamine induces mitochondrial ERK activation. Free Radic Biol Med (2007) 1.32
The role of environmental exposures in neurodegeneration and neurodegenerative diseases. Toxicol Sci (2011) 1.31
PINK1 defect causes mitochondrial dysfunction, proteasomal deficit and alpha-synuclein aggregation in cell culture models of Parkinson's disease. PLoS One (2009) 1.30
Mitochondrial biology and Parkinson's disease. Cold Spring Harb Perspect Med (2012) 1.30
Tissue- and cell-type-specific manifestations of heteroplasmic mtDNA 3243A>G mutation in human induced pluripotent stem cell-derived disease model. Proc Natl Acad Sci U S A (2013) 1.28
Loss of mitochondrial complex I activity potentiates dopamine neuron death induced by microtubule dysfunction in a Parkinson's disease model. J Cell Biol (2011) 1.28
Mitochondrial dynamics in Parkinson's disease. Exp Neurol (2009) 1.24
Pink1 regulates the oxidative phosphorylation machinery via mitochondrial fission. Proc Natl Acad Sci U S A (2011) 1.24
Gene transfer of a reserpine-sensitive mechanism of resistance to N-methyl-4-phenylpyridinium. Proc Natl Acad Sci U S A (1992) 1.23
Role of oxidative stress in Parkinson's disease. Exp Neurobiol (2013) 1.23
Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease. J Neural Transm (Vienna) (2010) 1.22
Mitochondrial medicine for aging and neurodegenerative diseases. Neuromolecular Med (2008) 1.22
Mitochondria and cell bioenergetics: increasingly recognized components and a possible etiologic cause of Alzheimer's disease. Antioxid Redox Signal (2011) 1.21
Innate and adaptive immunity for the pathobiology of Parkinson's disease. Antioxid Redox Signal (2009) 1.20
Mitochondrial DNA polymorphisms as risk factors for Parkinson's disease and Parkinson's disease dementia. Hum Genet (2004) 1.19
Platelet-mediated transformation of mtDNA-less human cells: analysis of phenotypic variability among clones from normal individuals--and complementation behavior of the tRNALys mutation causing myoclonic epilepsy and ragged red fibers. Am J Hum Genet (1994) 1.19
Mitochondria as a therapeutic target for aging and neurodegenerative diseases. Curr Alzheimer Res (2011) 1.17
The neurodegenerative mitochondriopathies. J Alzheimers Dis (2009) 1.14
Characterization of intracellular elevation of glutathione (GSH) with glutathione monoethyl ester and GSH in brain and neuronal cultures: relevance to Parkinson's disease. Exp Neurol (2006) 1.14
Maternal transmission of Alzheimer's disease: prodromal metabolic phenotype and the search for genes. Hum Genomics (2010) 1.12
Neuroprotective function of DJ-1 in Parkinson's disease. Oxid Med Cell Longev (2013) 1.12
Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases. Neuromolecular Med (2008) 1.10
Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci U S A (1994) 1.09
Involvment of cytosolic and mitochondrial GSK-3beta in mitochondrial dysfunction and neuronal cell death of MPTP/MPP-treated neurons. PLoS One (2009) 1.09
The three 'P's of mitophagy: PARKIN, PINK1, and post-translational modifications. Genes Dev (2015) 1.08
Traumatic brain injury in adult rats causes progressive nigrostriatal dopaminergic cell loss and enhanced vulnerability to the pesticide paraquat. J Neurotrauma (2011) 1.08
Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease model. Free Radic Biol Med (2010) 1.07
Mitochondrial neuronal uncoupling proteins: a target for potential disease-modification in Parkinson's disease. Transl Neurodegener (2012) 1.06
Altered dopamine metabolism and increased vulnerability to MPTP in mice with partial deficiency of mitochondrial complex I in dopamine neurons. Hum Mol Genet (2011) 1.06
The mitochondrial chaperone protein TRAP1 mitigates α-Synuclein toxicity. PLoS Genet (2012) 1.06
The role of PTEN-induced kinase 1 in mitochondrial dysfunction and dynamics. Int J Biochem Cell Biol (2009) 1.05
Mitochondrial dysfunction in idiopathic Parkinson disease. Am J Hum Genet (1998) 1.04
Metabolic profiling of Parkinson's disease: evidence of biomarker from gene expression analysis and rapid neural network detection. J Biomed Sci (2009) 1.03
NRF2 activation restores disease related metabolic deficiencies in olfactory neurosphere-derived cells from patients with sporadic Parkinson's disease. PLoS One (2011) 1.02
Distinct effects of rotenone, 1-methyl-4-phenylpyridinium and 6-hydroxydopamine on cellular bioenergetics and cell death. PLoS One (2012) 1.02
Melatonin in Alzheimer's disease and other neurodegenerative disorders. Behav Brain Funct (2006) 1.01
Mitochondrial dysfunctions in neurodegenerative diseases: relevance to Alzheimer's disease. Biomed Res Int (2014) 1.01
Soluble, prefibrillar α-synuclein oligomers promote complex I-dependent, Ca2+-induced mitochondrial dysfunction. J Biol Chem (2014) 1.00
Neuroprotective effect of long-term NDI1 gene expression in a chronic mouse model of Parkinson disorder. Rejuvenation Res (2009) 0.99
Mitochondrial Dysfunction: The Road to Alpha-Synuclein Oligomerization in PD. Parkinsons Dis (2011) 0.99
A mitocentric view of Parkinson's disease. Annu Rev Neurosci (2014) 0.99
Mitochondria in neurodegeneration. Adv Exp Med Biol (2012) 0.97
Analysis of the mitochondrial proteome in multiple sclerosis cortex. Biochim Biophys Acta (2011) 0.97
Mitochondria and energetic depression in cell pathophysiology. Int J Mol Sci (2009) 0.95
Differential modulation of Akt/glycogen synthase kinase-3beta pathway regulates apoptotic and cytoprotective signaling responses. J Biol Chem (2008) 0.95
Coenzyme Q10: is there a clinical role and a case for measurement? Clin Biochem Rev (2008) 0.95
Intrastriatal lipopolysaccharide injection induces parkinsonism in C57/B6 mice. J Neurosci Res (2009) 0.94
Behavioral and metabolic characterization of heterozygous and homozygous POLG mutator mice. Mitochondrion (2013) 0.94
Gene-environment interactions in Parkinson's disease: specific evidence in humans and mammalian models. Neurobiol Dis (2012) 0.94
Association of glycogen synthase kinase-3β with Parkinson's disease (review). Mol Med Rep (2014) 0.94
The interplay of neuronal mitochondrial dynamics and bioenergetics: implications for Parkinson's disease. Neurobiol Dis (2012) 0.93
Bioenergetic medicine. Br J Pharmacol (2014) 0.93
Mutational screening of the mortalin gene (HSPA9) in Parkinson's disease. J Neural Transm (Vienna) (2009) 0.93
Mitochondrial dynamics and mitophagy in Parkinson's disease: disordered cellular power plant becomes a big deal in a major movement disorder. Curr Opin Neurobiol (2011) 0.93
Complex I polymorphisms, bigenomic heterogeneity, and family history in Virginians with Parkinson's disease. J Neurol Sci (2006) 0.93
Estrogen protection in Friedreich's ataxia skin fibroblasts. Endocrinology (2011) 0.92
Microtubule depolymerization potentiates alpha-synuclein oligomerization. Front Aging Neurosci (2010) 0.92
Parkinson's disease as a result of aging. Aging Cell (2015) 0.92
Mitochondrial metabolism in Parkinson's disease impairs quality control autophagy by hampering microtubule-dependent traffic. Hum Mol Genet (2012) 0.91
Role and treatment of mitochondrial DNA-related mitochondrial dysfunction in sporadic neurodegenerative diseases. Curr Pharm Des (2011) 0.90
Novel, high-intensity exercise prescription improves muscle mass, mitochondrial function, and physical capacity in individuals with Parkinson's disease. J Appl Physiol (1985) (2014) 0.90
Genes and parkinsonism. J Neurol Neurosurg Psychiatry (1997) 0.89
Oxidative stress in skin fibroblasts cultures from patients with Parkinson's disease. BMC Neurol (2010) 0.87
Sequential and concerted gene expression changes in a chronic in vitro model of parkinsonism. Neuroscience (2008) 0.87
Parkin and PINK1 parkinsonism may represent nigral mitochondrial cytopathies distinct from Lewy body Parkinson's disease. Parkinsonism Relat Disord (2009) 0.87
Mitochondrial dysfunction in the striatum of aged chronic mouse model of Parkinson's disease. Front Aging Neurosci (2009) 0.87
Maternal inheritance and mitochondrial DNA variants in familial Parkinson's disease. BMC Med Genet (2010) 0.87
Monomer DJ-1 and its N-terminal sequence are necessary for mitochondrial localization of DJ-1 mutants. PLoS One (2013) 0.86
Mitochondrial dysfunction in Parkinson's disease: pathogenesis and neuroprotection. Parkinsons Dis (2010) 0.86
PGC-1α Promoter Methylation in Parkinson's Disease. PLoS One (2015) 0.85
Mitochondrial fusion/fission, transport and autophagy in Parkinson's disease: when mitochondria get nasty. Parkinsons Dis (2011) 0.85
Unregulated mitochondrial GSK3beta activity results in NADH: ubiquinone oxidoreductase deficiency. Neurotox Res (2008) 0.85
Cybrids in Alzheimer's disease: a cellular model of the disease? Neurology (1997) 2.85
Electron transport chain defects in Alzheimer's disease brain. Neurology (1994) 2.51
Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol (1996) 2.22
Cytochrome oxidase deficiency in Alzheimer's disease. Neurology (1990) 1.96
Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol (1999) 1.81
Abnormal mitochondrial morphology in sporadic Parkinson's and Alzheimer's disease cybrid cell lines. Exp Neurol (2000) 1.80
Quantitative autoradiographic localization of the D1 and D2 subtypes of dopamine receptors in rat brain. J Neurosci (1986) 1.76
Evidence for a defect in NADH: ubiquinone oxidoreductase (complex I) in Huntington's disease. Neurology (1990) 1.67
A defect in mitochondrial electron-transport activity (NADH-coenzyme Q oxidoreductase) in Leber's hereditary optic neuropathy. N Engl J Med (1989) 1.61
Role of mitochondria in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord (2000) 1.51
Reduced platelet cytochrome c oxidase activity in Alzheimer's disease. Neurology (1994) 1.43
Calcium homeostasis and reactive oxygen species production in cells transformed by mitochondria from individuals with sporadic Alzheimer's disease. J Neurosci (1997) 1.36
The parkinsonian neurotoxin MPP+ opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism. Biochim Biophys Acta (1999) 1.23
Alzheimer's disease cybrids replicate beta-amyloid abnormalities through cell death pathways. Ann Neurol (2000) 1.20
Cytochrome c oxidase in Alzheimer's disease brain: purification and characterization. Neurology (1995) 1.17
Mitochondria in sporadic amyotrophic lateral sclerosis. Exp Neurol (1998) 1.09
Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson's disease family. Ann Neurol (1998) 1.04
Persistence of neurochemical changes in dopamine systems after repeated cocaine administration. J Pharmacol Exp Ther (1990) 0.99
Propionate inhibition of succinate:CoA ligase (GDP) and the citric acid cycle in mitochondria. Pediatr Res (1980) 0.97
Mitochondrial dysfunction in cybrid lines expressing mitochondrial genes from patients with progressive supranuclear palsy. J Neurochem (2000) 0.96
Friedreich ataxia: III. Mitochondrial malic enzyme deficiency. Neurology (1982) 0.94
Chronic reduction in complex I function alters calcium signaling in SH-SY5Y neuroblastoma cells. Brain Res (2001) 0.92
Spin trapping of azidyl and hydroxyl radicals in azide-inhibited rat brain submitochondrial particles. Arch Biochem Biophys (1994) 0.92
Inhibitory effects of sodium valproate on oxidative phosphorylation. Neurology (1981) 0.90
Cyclosporin A increases resting mitochondrial membrane potential in SY5Y cells and reverses the depressed mitochondrial membrane potential of Alzheimer's disease cybrids. Biochem Biophys Res Commun (1998) 0.90
Platelet mitochondrial respiratory chain function in Parkinson's disease. Mov Disord (1997) 0.89
Human mitochondrial electron transport chain: assay of succinate: cytochrome c reductase in leukocytes, platelets and cultured fibroblasts. Biochem Med (1981) 0.87
Association of the mitochondrial 8344 MERRF mutation with maternally inherited spinocerebellar degeneration and Leigh disease. Neurology (1996) 0.86
Cytochrome oxidase inhibition: a novel animal model of Alzheimer's disease. J Geriatr Psychiatry Neurol (1992) 0.85
Friedreich ataxia. II. Normal kinetics of lipoamide dehydrogenase. Neurology (1979) 0.85
Biochemical analysis of cybrids expressing mitochondrial DNA from Contursi kindred Parkinson's subjects. Exp Neurol (2001) 0.83
Lipoamide dehydrogenase deficiency with primary lactic acidosis: favorable response to treatment with oral lipoic acid. J Pediatr (1984) 0.82
Characterization of cybrid cell lines containing mtDNA from Huntington's disease patients. Biochem Biophys Res Commun (1999) 0.82
Friedreich's ataxia: I. Normal pyruvate dehydrogenase complex activity in platelets. Ann Neurol (1978) 0.81
Loosely coupled mitochondrial oxidative phosphorylation induced by protoporphyrin. Biochem Med (1979) 0.81
Protonmotive force in muscle mitochondria. Muscle Nerve (1982) 0.80
Parkinson's disease and the electron transport chain. Ann Neurol (1991) 0.80
Psychiatric effects of selegiline. Arch Neurol (1991) 0.80
Mitochondrial function after asphyxia in newborn lambs. Stroke (1989) 0.79
Friedreich's disease: IV. Reduced mitochondrial malic enzyme activity in heterozygotes. Neurology (1983) 0.79
Sensitization to cocaine in the nigrostriatal dopamine system. NIDA Res Monogr (1988) 0.79
Secondary inhibition of 2-ketoglutarate dehydrogenase complex by MPTP. Neuroreport (1998) 0.79
Mitochondrial DNA-depleted neuroblastoma (Rho degrees) cells exhibit altered calcium signaling. Biochim Biophys Acta (2000) 0.79
Chewing oscillopsia. Arch Neurol (1984) 0.79
Inactivation of beef brain alpha-ketoglutarate dehydrogenase complex by valproic acid and valproic acid metabolites. Possible mechanism of anticonvulsant and toxic actions. J Clin Invest (1990) 0.78
Effects of chronic treatment with selective and nonselective antagonists on the subtypes of dopamine receptors. Synapse (1989) 0.77
Chronic treatment with levodopa and/or selegiline does not affect behavioral recovery induced by fetal ventral mesencephalic grafts in unilaterally 6-hydroxydopamine-lesioned rats. Exp Neurol (1994) 0.76
Conditioned apomorphine-induced turning in 6-OHDA-lesioned rats. Pharmacol Biochem Behav (1994) 0.76
Long-term treatment of male F344 rats with deprenyl: assessment of effects on longevity, behavior, and brain function. Neurobiol Aging (1997) 0.76
Parkinson disease in twins. JAMA (1999) 0.75
Treatment of Parkinson's disease. Neurology (1990) 0.75
Bilirubin increases mitochondrial inner membrane conductance. Biochem Med (1985) 0.75
Bethanechol for anticholinergic side effects. Ann Neurol (1988) 0.75
Myxothiazol resistance in human mitochondria. Biochim Biophys Acta (1988) 0.75
Control of cerebral blood flow. Ann Neurol (1988) 0.75
Preclinical detection of Parkinson's disease: biochemical approaches. Neurology (1991) 0.75
Mitochondrial impact on nerve growth factor production in vascular smooth muscle-derived cells. Biochim Biophys Acta (1999) 0.75
Urea cycle regulation: I. Coupling of ornithine metabolism to mitochondrial oxidative phosphorylation. Neurology (1980) 0.75
A mechanism of toxicity of isovaleric acid in rat liver mitochondria. Biochem Med (1982) 0.75
Developmental changes in newborn lamb brain mitochondrial activity and postasphyxial lipid peroxidation. Proc Soc Exp Biol Med (1995) 0.75